Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed

Singapore Deputy PM stresses preparation for next pandemic

Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.

Triomphe
Thomas Triomphe, executive VP, head of vaccines, Sanofi • Source: Sanofi

More from Business

More from Scrip